Paul Hastings LLP has advised Ligand Pharmaceuticals Incorporated in connection with its private placement. Ligand Pharmaceuticals Incorporated has completed a private placement of $700 million aggregate...
Ligand Pharmaceuticals Completes $700 Million Convertible Senior Notes Private Placement
Ligand Pharmaceuticals to Acquire XOMA Royalty for $739 Million
Paul Hastings LLP has advised Ligand Pharmaceuticals Incorporated. Gibson Dunn has advised XOMA Royalty Corporation. Ligand Pharmaceuticals Incorporated has entered into a definitive agreement to acquire...
Ligand Pharmaceuticals’ Acquisition of APEIRON Biologics
McDermott Will & Emery and E+H Rechtsanwälte advise Ligand Pharmaceuticals Incorporated on the deal. Ligand Pharmaceuticals Incorporated announced the acquisition of all shares in the Austrian...
Ligand’s Spin-off of OmniAb Business
Latham & Watkins represented Ligand in the transaction, while Weil, Gotshal & Manges represented APAC. Ligand Pharmaceuticals Incorporated has announced the signing of a definitive merger...